Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager
Molecular Therapy Oncology · 2026-06 · 34 (2) · 201201
DOI: 10.1016/j.omton.2026.201201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Oncology, 2026-06. Verfasst von Moon Jung Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Legorreta Cancer Center of Brown University, Providence, RI 02903, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, Brown University, Brown University Warren Alpert Medical School.
Abstract (Originalsprache)
Recent clinical trials show that CAR T cell therapies can initially blunt tumor growth in patients with glioblastoma (GBM). However, therapeutic efficacy remains limited by the immunosuppressive tumor microenvironment and restricted immune cell trafficking across the blood-brain barrier (BBB). To counteract these challenges, we have utilized the oncolytic adenovirus (OV) Ad5-Δ24-RGD as a platform to overexpress a bispecific T cell engager (BiTE) targeting both CD3 on T cells and the GBM-specific tumor associated antigen IL-13Rα2. We first demonstrated that OV-BiTE can significantly increase the recruitment of T cells to GBM, both in vitro and in vivo. Moreover, OV-BiTE treatment also markedly enhanced CAR T cell infiltration and tumor cytotoxicity in a GBM-BBB spheroid model, possibly through downregulation of endothelial junction protein expression. We then showed that intratumoral injection of OV-BiTE followed by infusion of combined EGFR and EGFRvIII CAR T cells was more effective than OV-BiTE supplemented with either CAR T therapy alone and led to significant tumor reduction in a GBM xenograft mouse model. In conclusion, our multimodal OV-BiTE plus CAR T cell immunotherapy is capable of overcoming the immunosuppressive tumor microenvironment and GBM resistance to treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Legorreta Cancer Center of Brown University, Providence, RI 02903, USA.
- Division of Hematology and Oncology, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
- Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
- Division of Rheumatology, Department of Medicine, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
- Department of Neurosurgery, Rhode Island Hospital and The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Förderung
- National Institutes of Health
- Brown University
- Brown University Warren Alpert Medical School
- Rhode Island Hospital
Zitieren
APA
Choi, M. J., So, E. Y., Akosman, B., Lee, Y. E., Raufi, A. G., Reginato, A. M., Chen, C. C., Lawler, S. E., Wong, E. T., & Liang, O. D. (2026). Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager. Molecular Therapy Oncology, 34(2), 201201. https://doi.org/10.1016/j.omton.2026.201201
Vancouver
Choi MJ, So EY, Akosman B, Lee YE, Raufi AG, Reginato AM, et al. Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager. Molecular Therapy Oncology. 2026;34(2):201201. doi:10.1016/j.omton.2026.201201
BibTeX
@article{Choi2026,
author = {Choi, Moon Jung and So, Eui Young and Akosman, Bedia and Lee, Young Eun and Raufi, Alexander G and Reginato, Anthony M and Chen, Clark C and Lawler, Sean E and Wong, Eric T and Liang, Olin D},
title = {Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {2},
pages = {201201},
doi = {10.1016/j.omton.2026.201201}
}
EUVIMED